Boehringer Ingelheim News

Pharmaceutical news of Boehringer Ingelheim GmbH in Germany

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin

Ingelheim/Germany, 28 September 2009 - Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials.

Boehringer Ingelheim RSS-Newsfeed

RSS newsfeed of Boehringer Ingelheim GmbH in Germany

Syndicate content